[Rinsho ketsueki] The Japanese journal of clinical hematology · 2009
Fractionated administration of gemtuzumab ozogamicin for refractory acute myeloid leukemia.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
YAHAGI Yuichi, USUI Noriko, YAMAGUCHI Yuko, DOBASHI Nobuaki, YANO Shingo, TAKEI Yutaka, SUGIYAMA Katsuki, TAKAHARA Shinobu, SAITO Takeshi, MINAMI Jiro, KOBAYASHI Tatsunosuke, KAMIYAMA Yutaro, MORIKAWA Tetsuyuki, AIBA Keisuke
Аннотация
It is difficult to decide an appropriate treatment strategy for elderly leukemia patients with other complications. We encountered 2 cases of refractory acute myeloid leukemia and safely treated the patients with fractionated administration of gemtuzumab ozogamicin (GO). Standard induction therapies were not effective for these patients. Moreover, they suffered from complications due to which their treatment options were restricted. Fractionated administration of GO (GO 3 mg/m(2) on days 1, 3 and 5) was accomplished safely and alleviated the patients' conditions. After treatment, these patients were followed by outpatient basis. We consider that this is an impressive treatment because fractionated administration of GO is potentially less toxic. Further, it will be helpful to maintain or improve the QOL of patients who are unable to receive intensive chemotherapy. These cases were significant because fractionated GO treatment is potentially less toxic and it will be helpful to maintain or improve the QOL of patients who can not receive intensive chemotherapy.